Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Новые подходы к диагностике и лечению инфекции мочевой системы у детей И.Н.Захарова, А.Н.Горяйнова, Э.Б.Мумладзе, В.В.Кучерова, Ю.А.Дмитриева ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ, Москва
Новые подходы к диагностике и лечению инфекции мочевой системы у детей И.Н.Захарова, А.Н.Горяйнова, Э.Б.Мумладзе, В.В.Кучерова, Ю.А.Дмитриева ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ, Москва
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Коровина Н.А., Захарова И.Н., Страчунский Л.С. и др. Практические рекомендации по антибактериальной терапии инфекции мочевой системы внебольничного происхождения у детей. Клин. микробиология и антимикроб. химиотерапия. 2002; 4 (4): 337–46.
2. Bachur R, Harper MB. Reliability of the urinalysis for predicting urinary tract infections in young febrile children. Arch Pediatr Adolesc Med 2001; 155 (1): 60–5.
3. Ramage IJ et al. Primary vesicoureteric reflux diagnosed in the 1st month of life. Pediatr Nephrol 1999; 13 (8): 716–7.
4. Guidelines on urological infections. Ed. by M.Grabe et al. European association of urology, 2010.
5. Urinary tract infection in children: diagnosis, treatment and long-term management (NICE clinical guideline 54). National institute for health and clinical excellence, London, 2007.
6. Ma JF, Shortliffe LM. Urinary tract infection in children: etiology and epidemiology. Urol Clin North Am 2004; 31 (3): 517–26.
7. Cavagnaro F. Urinary tract infection in childhood. Rev Chilena Infectol 2005; 22 (2): 161–8.
8. Le Moullec JM, Jullienne A, Chenais J et al. The complete seguence of human preprocalcitonin. FEBC 1984; 167: 93–7.
9. Benador N, Siegrist CA, Gendrel D et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 1998; 102: 1422–5.
10. Prat C, Dominguez J, Rodrigo C et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 2003; 22: 438–42.
11. Christian MT, McColl JH, MacKenzie JR et al. Risk assessment of renal cortical scarring with urinary tract infection by clinical features and ultrasonography. Arch Dis Child 2000; 83 (5): 457.
12. Anderson NG, Allan RB, Abbott GD. Fluctuating fetal renal pelvis: marker of high-grade vesicoureteral reflux. Pediatr Nephrol 2004; 19 (7): 749–53.
13. Garin EH et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117 (3): 626–32.
14. Swerkersson S et al. Relationship among vesicoureteral reflux, urinary tract infection and renal damage in children. J Urol 2007; 178 (2): 647–51.
15. Ataei N et al. Evaluation of acute pyelonephritis with DMSA scans in children presenting after the age of 5 years. Pediatr Nephrol 2005; 20 (10): 1439–44.
16. Coulthard MC et al. A nurse lrd education and direct access service for the management of urinary tract infection. Prospective controlled trial. BMJ 2003; 327 (7416): 20–5.
17. Doganis D, Siafas K, Mavrikou M et al. Does early treatment of urinary tract infection prevent renal damage? Pediatrics 2007; 120 (4): e922–8.
18. Hiraoka M, Hashimoto G, Tsuchida et al. Early treatment of urinary infection prevents renal damage on cortical scintigraphy. Pediatr Nephrology 2003; 18 (2): 115–8.
19. American Academy of Pediatrics: Practice Parameter: The Diagnosis, Treatment, and Evaluation of the initial Urinary Tract Infection in Febrile Infants and Young Children. Pediatrics 1999; 103 (4): 843–52.
20. Bloomfield P, Hodsson EM, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2005; 25 (1): CD003772.
21. Garin EH et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117 (3): 626–32.
22. Hellerstein S. Antibiotic treatment for urinary tract infections in pediatric patients. Minerva Pediatr 2003; 55 (5): 395–406.
23. Hodson EM, Willis NS, Craig JC. Antibitic for acute pyelonephritis in children. Cochrane Database Syst Rev 2007; 17 (4): CD003772.
24. Keren R, Chan E. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infection in children. Pediatrics 2002; 109 (5): E70.
25. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev 2007; 17 (4): CD003237.
26. Schlager TA. Urinary tract infections in children younger than 5 years of age: epidemiology, diagnosis, treatment, outcomes and prevention. Paediatr Drugs 2001; 3 (3): 219–27.
27. Verrier-Jones K et al. Urinary tract infection in children (diagnosis, treatment and long-term management). London, 2007; p. 149.
28. Williams GJ, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 19 (3): CD001534.
29. Коровина Н.А., Захарова И.Н., Заплатников А.Л. и др. Фармакотерапия инфекции мочевой системы у детей. Руководство для врачей-педиатров. М., 2006.
2. Bachur R, Harper MB. Reliability of the urinalysis for predicting urinary tract infections in young febrile children. Arch Pediatr Adolesc Med 2001; 155 (1): 60–5.
3. Ramage IJ et al. Primary vesicoureteric reflux diagnosed in the 1st month of life. Pediatr Nephrol 1999; 13 (8): 716–7.
4. Guidelines on urological infections. Ed. by M.Grabe et al. European association of urology, 2010.
5. Urinary tract infection in children: diagnosis, treatment and long-term management (NICE clinical guideline 54). National institute for health and clinical excellence, London, 2007.
6. Ma JF, Shortliffe LM. Urinary tract infection in children: etiology and epidemiology. Urol Clin North Am 2004; 31 (3): 517–26.
7. Cavagnaro F. Urinary tract infection in childhood. Rev Chilena Infectol 2005; 22 (2): 161–8.
8. Le Moullec JM, Jullienne A, Chenais J et al. The complete seguence of human preprocalcitonin. FEBC 1984; 167: 93–7.
9. Benador N, Siegrist CA, Gendrel D et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 1998; 102: 1422–5.
10. Prat C, Dominguez J, Rodrigo C et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 2003; 22: 438–42.
11. Christian MT, McColl JH, MacKenzie JR et al. Risk assessment of renal cortical scarring with urinary tract infection by clinical features and ultrasonography. Arch Dis Child 2000; 83 (5): 457.
12. Anderson NG, Allan RB, Abbott GD. Fluctuating fetal renal pelvis: marker of high-grade vesicoureteral reflux. Pediatr Nephrol 2004; 19 (7): 749–53.
13. Garin EH et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117 (3): 626–32.
14. Swerkersson S et al. Relationship among vesicoureteral reflux, urinary tract infection and renal damage in children. J Urol 2007; 178 (2): 647–51.
15. Ataei N et al. Evaluation of acute pyelonephritis with DMSA scans in children presenting after the age of 5 years. Pediatr Nephrol 2005; 20 (10): 1439–44.
16. Coulthard MC et al. A nurse lrd education and direct access service for the management of urinary tract infection. Prospective controlled trial. BMJ 2003; 327 (7416): 20–5.
17. Doganis D, Siafas K, Mavrikou M et al. Does early treatment of urinary tract infection prevent renal damage? Pediatrics 2007; 120 (4): e922–8.
18. Hiraoka M, Hashimoto G, Tsuchida et al. Early treatment of urinary infection prevents renal damage on cortical scintigraphy. Pediatr Nephrology 2003; 18 (2): 115–8.
19. American Academy of Pediatrics: Practice Parameter: The Diagnosis, Treatment, and Evaluation of the initial Urinary Tract Infection in Febrile Infants and Young Children. Pediatrics 1999; 103 (4): 843–52.
20. Bloomfield P, Hodsson EM, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2005; 25 (1): CD003772.
21. Garin EH et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117 (3): 626–32.
22. Hellerstein S. Antibiotic treatment for urinary tract infections in pediatric patients. Minerva Pediatr 2003; 55 (5): 395–406.
23. Hodson EM, Willis NS, Craig JC. Antibitic for acute pyelonephritis in children. Cochrane Database Syst Rev 2007; 17 (4): CD003772.
24. Keren R, Chan E. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infection in children. Pediatrics 2002; 109 (5): E70.
25. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev 2007; 17 (4): CD003237.
26. Schlager TA. Urinary tract infections in children younger than 5 years of age: epidemiology, diagnosis, treatment, outcomes and prevention. Paediatr Drugs 2001; 3 (3): 219–27.
27. Verrier-Jones K et al. Urinary tract infection in children (diagnosis, treatment and long-term management). London, 2007; p. 149.
28. Williams GJ, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 19 (3): CD001534.
29. Коровина Н.А., Захарова И.Н., Заплатников А.Л. и др. Фармакотерапия инфекции мочевой системы у детей. Руководство для врачей-педиатров. М., 2006.
Авторы
И.Н.Захарова, А.Н.Горяйнова, Э.Б.Мумладзе, В.В.Кучерова, Ю.А.Дмитриева
ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ, Москва
ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.